Two 6-week, randomized, double-blind, placebo-controlled studies of ziprasidone in outpatients with bipolar I depression: did baseline characteristics impact trial outcome?

scientific article published in August 2012

Two 6-week, randomized, double-blind, placebo-controlled studies of ziprasidone in outpatients with bipolar I depression: did baseline characteristics impact trial outcome? is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1097/JCP.0B013E31825CCDE5
P698PubMed publication ID22722504

P2093author name stringIlise Lombardo
Sheela Kolluri
Gary Sachs
Ruoyong Yang
Charlotte Kremer
P433issue4
P407language of work or nameEnglishQ1860
P921main subjectplaceboQ269829
P304page(s)470-478
P577publication date2012-08-01
P1433published inJournal of Clinical PsychopharmacologyQ6294969
P1476titleTwo 6-week, randomized, double-blind, placebo-controlled studies of ziprasidone in outpatients with bipolar I depression: did baseline characteristics impact trial outcome?
P478volume32

Reverse relations

cites work (P2860)
Q38090854A systematic review of the evidence for the treatment of acute depression in bipolar I disorder
Q34475987Antipsychotics as antidepressants
Q38297860Balancing benefits and harms of treatments for acute bipolar depression
Q38297855Current landscape, unmet needs, and future directions for treatment of bipolar depression
Q36588607Evidence review and clinical guidance for the use of ziprasidone in Canada
Q46300154Guidelines for the recognition and management of mixed depression
Q38507842Important clinical features of atypical antipsychotics in acute bipolar depression that inform routine clinical care: a review of pivotal studies with number needed to treat
Q34515834LURASIDONE IN THE LONG-TERM TREATMENT OF PATIENTS WITH BIPOLAR DISORDER: A 24-WEEK OPEN-LABEL EXTENSION STUDY
Q39164212Lurasidone compared to other atypical antipsychotic monotherapies for bipolar depression: A systematic review and network meta-analysis
Q38297863Managing the side effects associated with commonly used treatments for bipolar depression
Q38342840Non-pharmacological strategies for treatment of inpatient depression
Q89665746Personalized Pharmacotherapy for Bipolar Disorder: How to Tailor Findings From Randomized Trials to Individual Patient-Level Outcomes
Q34349641Pharmacological management of bipolar depression: acute treatment, maintenance, and prophylaxis
Q26747670Pharmacotherapy of Acute Bipolar Depression in Adults: An Evidence Based Approach
Q36017024Randomized, placebo-controlled, adjunctive study of armodafinil for bipolar I depression: implications of novel drug design and heterogeneity of concurrent bipolar maintenance treatments
Q39013963Safety and efficacy of adjunctive second-generation antidepressant therapy with a mood stabiliser or an atypical antipsychotic in acute bipolar depression: a systematic review and meta-analysis of randomised placebo-controlled trials
Q28066714The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 2: Review, Grading of the Evidence, and a Precise Algorithm
Q38931913The Psychiatric Inclusion and Exclusion Criteria in Placebo-Controlled Monotherapy Trials of Bipolar Depression: An Analysis of Studies of the Past 20 Years
Q38697937The development of lurasidone for bipolar depression
Q38208032The effectiveness of lurasidone as an adjunct to lithium or divalproex in the treatment of bipolar disorder
Q38269372Treatment of bipolar depression: making sensible decisions

Search more.